Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study
The unmatched ENZA cohort had higher average age and more comorbidities than the AA cohort, but no meaningful differences were noted after PSM. ENZA was associated with a significantly lower risk of CV events and improved OS.
Authors
- Axel S. Merseburger (ORCID: https://orcid.org/0000-0001-6467-3931)
- Sophia Junker (ORCID: https://orcid.org/0000-0002-1434-9380)
- Carsten‐Henning Ohlmann (ORCID: https://orcid.org/0000-0003-1562-5364)
- Andrew Chilelli (ORCID: https://orcid.org/0009-0006-7086-4703)
- Eugen Dornstauder
- A. Serikoff
- Matthias Stoelzel (ORCID: https://orcid.org/0000-0002-2058-7385)
- Stefan G. Spitzer (ORCID: https://orcid.org/0000-0001-7822-2154)
- Philipp Hahn
- Armen Garo Aprikian
Institutions
- Wismar University of Applied Sciences (DE)
- McGill University Health Centre (CA)
- Astellas Pharma (United Kingdom) (GB)
- University Hospital Schleswig-Holstein (DE)
- Astellas Pharma (Germany) (DE)
- Johanniter-Krankenhaus Bonn (DE)
- Astellas Pharma (Netherlands) (NL)
- Klinik und Poliklinik für Psychotherapie und Psychosomatik (DE)
- McGill University (CA)
- Brandenburg University of Technology Cottbus-Senftenberg (DE)
- Technische Universität Dresden (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-03-02
- DOI
- https://doi.org/10.1007/s12325-025-03132-8
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Pfizer
- Astellas Pharma US